HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon Q1

This article was originally published in The Rose Sheet

Executive Summary

Firm is starting to recognize benefits from new product initiatives like relaunch of Revlon Age Defying makeup with Botafirm, CEO Jack Stahl says during May 6 analyst call. Makeup was the top-performing new product in the mass channel in Q1, Stahl points out, citing ACNielsen data, which include food, drug and mass outlets in the U.S. excluding Wal-Mart. However, Revlon brand as a whole lost market share, falling to 15.6% from 16.4% last year, while the firm's overall share was flat at 21.9%, exec notes. Success of new products was offset by performance of existing offerings, with net sales in North America falling 5.8% to $194 mil. International sales fared better, increasing 3.9% to $107 mil. Revlon net sales declined 2.4% to $300.9 mil. Net loss was $46.8 mil., compared to $58.2 mil. in Q1 2004...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel